由於分子生物學的迅速發展，更多的腫瘤指標及基因已逐步開發出來，雖然這些已分子生物為主的生物指標可以提供腫飛早期診斷情報，但它們仍不能提供腫瘤定位造影、特異性、臨床分予以及治療指標。本文以分子生物學為基礎，提供以鋒-99m標幟放射性藥物介入腫瘤診斷與治療之方向。

Improvement of scintigraphic tumor imaging is extensively determined by development of more tumor specific radiopharmaceuticals. Radionuclide imaging modalities (positron emission tomography， PET; single photon emission computed tomography， SPECT) are diagnostic cross-sectional imaging techniques that map the location and concentration of radionuclide-Iabeled radiotracers. Although CT and MRI provide considerable anatomic information about the location and the extent of tumors， these imaging modalities cannot adequately differentiate invasive lesions from edema， radiation necrosis or grading. PET and SPECT can be used to localize and characte'rize tumors by measuring metabolic activity. Due to favorable physical characteristics and low price， 99mTc radionuclide has been the choice for labeling. To improve the diagnosis， prognosis， planning and monitoring of treatment of cancer using functional pharmaceuticals， we have developed a series of 的mTc-labeledradiotracers. Application of molecular targets for cancer imaging and therapy are the major focus of this report.